Buckfire and Buckfire 1-800-606-1717
Call Now To Speak With
Michigan's Best Birth Injury Lawyers

FDA Approves Glycopyrrolate Oral Solution for Chronic Severe Drooling

The FDA has approved glycopyrrolate oral solution for the treatment of patients aged 3 to 16 years with chronic severe drooling associated with neurologic conditions, such as cerebral palsy. Medscape Medical News (Source: Medscape Today Headlines)

MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

African Ancestry Linked to Triple-Negative Breast Cancer

The FDA has approved glycopyrrolate oral solution for the treatment of patients aged 3 to 16 years with chronic severe drooling associated with neurologic conditions, such as cerebral palsy. Medscape Medical News (Source: Medscape Today Headlines)

A Proposed Evidence-Based Neonatal Work-up to Confirm or Refute Allegations of Intrapartum Asphyxia.

CONCLUSION:: The medical record of newborns with poor outcomes frequently has a paucity of objective, evidence-based data. This leads to speculation and unethical expert testimony. The protocol will assist in confirming or refuting allegations of intrapartum asphyxia. LEVEL OF EVIDENCE:: III. PMID: 20664384 [PubMed - in process] (Source: Obstetrics and Gynecology)

Chorioamnionitis and cerebral palsy: a meta-analysis.

CONCLUSION:: The significant association of clinical or histological chorioamnionitis with cerebral palsy suggested that clinical strategies to prevent or reduce chorioamnionitis would lead to a reduction in cerebral palsy. The culture techniques currently used to diagnose the presence of pathogenic microorganisms during pregnancy need to improve, both in their methodology and in the length of time they require. PMID: 20664400 [PubMed - in process] (Source: Obstetrics and Gynecology)

Coming out of the Americans with Disabilities Act (ADA) 20th Anniversary

(Source: United Cerebral Palsy National News)
Next Page »